Open AccessThe Landscape of the Advanced NSCLC Treatment Paradigm: Molecular Testing and Actionable Mutations
Author(s) -
Rasheda Persinger
Publication year - 2021
Publication title -
journal of the advanced practitioner in oncology
Language(s) - English
Resource type - Journals
eISSN - 2150-0886
pISSN - 2150-0878
DOI - 10.6004/jadpro.2021.12.3.17
Subject(s) - kras , medicine , ros1 , treatment modality , lung cancer , modalities , targeted therapy , cancer research , computational biology , oncology , cancer , adenocarcinoma , biology , colorectal cancer , social science , sociology
At JADPRO Live Virtual 2020, Rasheda Persinger, AGNP-C, explained the current lung cancer treatment landscape, including targeted therapies for EGFR and ALK rearrangements, as well as for BRAF, ROS1, NTRK, RET, MET , and KRAS mutations, and described the different testing modalities for molecular markers.